|
Array Biopharma's new asthma drug meets goal of improved lung function
Denver Post Array Biopharma Inc. said Tuesday, one of its drugs met the main goal of improving lung function in a mid-stage study among patients with mild to moderate persistent allergic asthma. Array shares rose 12.7 percent, or 71 cents, to $6.27 in morning … Array BioPharma: Study Shows Asthma Candidate ARRY-502 Improves Lung … Array BioPharma scores midstage success for asthma drug Array Shares Climb After Asthma Drug Shows Positive Phase 2 Results |
View full post on asthma – Google News